Moderna, Inc. (MRNA)
Crude Oil Moves Lower; Moderna Shares Plunge
U.S. stocks traded lower toward the end of trading, with the Dow Jones index dipping more than 650 points on Thursday.
Stock Of The Day: Moderna Stock Plunges, Breaking Key Support Levels Following Earnings Report
Moderna, Inc. MRNA shares are getting hit because of a bad earnings report. The Street didn't like the numbers.
Moderna (MRNA) Q2 2024 Earnings Call Transcript
Moderna Inc. (NASDAQ:MRNA ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Stéphane Bancel - Chief Executive Officer Stephen Hoge - President Jamey Mock - Chief Financial Officer Lavina Talukdar - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Michael Yee - Jefferies Elliott Bosco - UBS Gena Wang - Barclays Luca Issi - RBC Capital Alexandria Hammond - Bank of America Edward Tenthoff - Piper Sandler Jessica Fye - JP Morgan Evan Wang - Guggenheim Greg - TD Securities Adi - Evercore ISI Operator Good day and thank you for standing by. Welcome to the Moderna second quarter 2024 conference call.
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.
Moderna shares dive on slashed 2024 sales forecast
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plummeted almost 20% after the vaccine maker slashed its full-year sales forecast for respiratory vaccines by up to $1 billion. It now expects product sales for its respiratory franchise, which includes COVID-19 and respiratory syncytial virus (RSV) vaccines, to be between $3 billion to $3.5 billion, compared to its earlier projection of $4 billion.
Moderna's Revenue Warning Sends the Stock Into the Red for 2024
Moderna (MRNA) shares plunged after the COVID-19 vaccine maker slashed its outlook on lower demand in Europe and a tough market in the U.S.
Moderna Stock Gaps Lower After Earnings
Moderna Inc (NASDAQ:MRNA) stock is freefalling this morning, last seen down 15.2% to trade at $95.48 and pacing for its worst day since November 2021 after the company's second-quarter financial results.
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $3.33 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.62 per share a year ago.
Moderna's stock slides 12% after it lowers full year sales guidance
Moderna Inc.'s stock MRNA tumbled 12% premarket Thursday, after the biotech cut its sales guidance for 2024, offsetting a narrower-than-expected second-quarter loss and revenue that topped estimates. Moderna had a net loss of $1.3 billion, or $3.33 a share, for the quarter, after a loss of $1.4 billion, or $3.62 a share, in the year-earlier period.
Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market
Moderna reported second-quarter revenue that beat estimates and a narrower than-expected loss for the period. But the company slashed its full-year sales guidance, citing lower sales in Europe, a "competitive environment" for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025.
Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue
Moderna slashed its 2024 forecast for sales of its COVID-19 and respiratory syncytial virus vaccines by up to 25%, or $1 billion, on Thursday as it expects very low sales to the EU this year.
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June Announced positive Phase 3 data for combination vaccine against influenza and COVID-19 Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024. "During the second quarter, we marked the approval of our second mRNA product and significantly lowered our operating costs.
